Holen Sie sich die Stockscreener-App
2.18
1.40%
0.03
Handel nachbörslich:
2.15
-0.03
-1.38%
Schlusskurs vom Vortag:
$2.15
Offen:
$2.175
24-Stunden-Volumen:
46,911
Relative Volume:
0.51
Marktkapitalisierung:
$8.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.24M
KGV:
-0.3903
EPS:
-5.5853
Netto-Cashflow:
$-8.09M
1W Leistung:
-9.92%
1M Leistung:
+7.92%
6M Leistung:
-26.35%
1J Leistung:
-78.75%
1-Tages-Spanne:
$2.1301
$2.23
1-Wochen-Bereich:
$2.1301
$2.535
52-Wochen-Spanne:
$1.69
$10.71
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
3500 LENOX RD. NE, ATLANTA
Vergleichen Sie ALZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.18 | 8.17M | 0 | -6.24M | -8.09M | -5.5853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Community Health Systems Incs ROE strong enough2025 Biggest Moves & Real-Time Market Sentiment Reports - baoquankhu1.vn
Is Alzamend Neuro Inc. stock heavily shortedWeekly Profit Analysis & Daily Profit Maximizing Tips - bollywoodhelpline.com
Aug Sectors: Is Alzamend Neuro Inc stock heavily shortedJuly 2025 News Drivers & Weekly High Return Opportunities - baoquankhu1.vn
Bond Watch: Can Alzamend Neuro Inc stock beat market expectations this quarterQuarterly Growth Report & Capital Protection Trade Alerts - Bộ Nội Vụ
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell? - Defense World
Can Alzamend Neuro Inc. stock beat analyst upgradesJuly 2025 Outlook & Safe Entry Point Identification - ulpravda.ru
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Will Alzamend Neuro Inc. stock attract ESG investorsJuly 2025 Outlook & Precise Swing Trade Entry Alerts - Улправда
Will Alzamend Neuro Inc. stock return to pre crisis levelsJuly 2025 Short Interest & Safe Entry Zone Tips - ulpravda.ru
What technical charts say about Alzamend Neuro Inc. stockQuarterly Performance Summary & Reliable Price Breakout Alerts - ulpravda.ru
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Alzamend Neuro, Inc.Common Stock (NQ: ALZN - FinancialContent
Momentum Shift: Will Alzamend Neuro Inc stock attract ESG investorsEarnings Performance Report & Stepwise Trade Signal Implementation - Bộ Nội Vụ
Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN) - The Globe and Mail
Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq
ALZN: Ascendiant Capital Lowers Price Target, Maintains Buy Rati - GuruFocus
Decliners Report: Why Alzamend Neuro Inc. stock is recommended by analystsQuarterly Market Review & Detailed Earnings Play Strategies - Улправда
Will Alzamend Neuro Inc. stock deliver long term returnsWeekly Profit Analysis & Consistent Profit Trade Alerts - Улправда
Is Alzamend Neuro Inc. stock attractive for ETFs2025 Support & Resistance & Community Verified Trade Signals - Улправда
Can Alzamend Neuro Inc. stock maintain growth trajectoryWeekly Trade Analysis & Risk Managed Trade Strategies - DonanımHaber
Alzamend Neuro Earnings Notes - Trefis
Why Alzamend Neuro Inc. stock is recommended by analystsQuarterly Growth Report & Verified Momentum Watchlists - Улправда
Can Alzamend Neuro Inc. stock sustain market leadershipJuly 2025 Chart Watch & Consistent Return Investment Signals - Улправда
Alzamend Neuro, Inc. SEC 10-Q Report - TradingView
Is Alzamend Neuro Inc stock attractive for passive investorsWeekly Investment Summary & Weekly Top Gainers Alerts - BỘ NỘI VỤ
Why Alzamend Neuro Inc. stock remains undervaluedJuly 2025 Analyst Calls & High Accuracy Trade Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
Alzamend Neuro Mourns Loss of Director Andrew Woo - MSN
Is Alzamend Neuro Inc. stock attractive for passive investors2025 Earnings Impact & Daily Profit Focused Stock Screening - BỘ NỘI VỤ
Alzamend Neuro: Will Topline Data Spark Investor Interest? - RTTNews
Alzamend Neuro's AL001 formulation highlights its potential to treat disorders such a Alzheimer's - SelectScience
What margin trends mean for Alzamend Neuro Inc. stockWeekly Market Outlook & Verified Swing Trading Watchlists - newser.com
Why Alzamend Neuro Inc. stock could see breakout soonProduct Launch & High Return Trade Opportunity Guides - newser.com
Why Alzamend Neuro Inc. stock could benefit from AI revolutionTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Can Alzamend Neuro Inc. stock sustain revenue growthMarket Risk Analysis & Pattern Based Trade Signal System - newser.com
Will Alzamend Neuro Inc. stock rally after Fed decisionsJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - newser.com
Will Alzamend Neuro Inc. stock reach all time highs in 2025Exit Point & Daily Technical Forecast Reports - newser.com
Alzamend completes clinical portion of phase II trial for lithium therapy - Investing.com Nigeria
Published on: 2025-11-19 13:20:00 - newser.com
Alzamend Neuro announces passing of board member Andrew H. Woo By Investing.com - Investing.com Australia
Comparing Alzamend Neuro Inc. in custom built stock radarsWeekly Risk Summary & Weekly Momentum Picks - newser.com
Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital - MarketScreener
Alzamend rises after completing mid-stage brain lithium study - TradingView
Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - Benzinga
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):